Revolution Medicines (NASDAQ:RVMD) CFO Jack Anders Sells 35,750 Shares of Stock

Revolution Medicines, Inc. (NASDAQ:RVMD) CFO Jack Anders sold 35,750 shares of the firm’s stock in a transaction on Wednesday, November 11th. The stock was sold at an average price of $188.10, for a total value of $6,724,575.00. Following the completion of the sale, the chief financial officer directly owned 119,216 shares of the company’s stock, valued at $22,424,529.60. The trade was a 23.07% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Jack Anders also recently made the following trade(s):

• On Wednesday, September 16th, Jack Anders sold 4,053 shares of Revolution Medicines stock. The stock was sold at an average price of $199.24, for a total value of $807,519.72.

Revolution Medicines Stock Down 2.3%

NASDAQ:RVMD traded down $4.06 during mid-day trading on Friday, hitting $172.29. 2,654,066 shares of the company’s stock traded hands, compared to its average volume of 2,814,289. The company has a fifty day moving average of $195.24 and a 200 day moving average of $159.06. Revolution Medicines, Inc. has a twelve month low of $63.50 and a twelve month high of $224.31. The company has a market capitalization of $37.26 billion, a P/E ratio of -18.91 and a beta of 1.44. The company has a debt-to-equity ratio of 0.44, a quick ratio of 8.34 and a current ratio of 8.36.

Revolution Medicines (NASDAQ:RVMD) last released its quarterly earnings results on Wednesday, November 4th. The company reported ($1.90) EPS for the quarter, beating analysts’ consensus estimates of ($2.35) by $0.45. The business had revenue of $197.56 million during the quarter, compared to analysts’ expectations of $25.58 million. During the same quarter last year, the business posted ($1.61) earnings per share. On average, analysts forecast that Revolution Medicines, Inc. will post -7.41 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. Royal Bank Of Canada lifted their target price on shares of Revolution Medicines from $260.00 to $321.00 and gave the stock an “outperform” rating in a research note on Thursday, November 5th. Brookline Capital Markets assumed coverage on shares of Revolution Medicines in a report on Monday, September 28th. They issued a “buy” rating and a $318.00 price target for the company. Stifel Nicolaus lifted their price objective on shares of Revolution Medicines from $215.00 to $230.00 and gave the stock a “buy” rating in a research note on Wednesday, September 9th. Oppenheimer boosted their price objective on shares of Revolution Medicines from $230.00 to $260.00 and gave the company an “outperform” rating in a report on Thursday, August 27th. Finally, The Goldman Sachs Group started coverage on Revolution Medicines in a research report on Thursday, September 24th. They issued a “buy” rating and a $267.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $262.75.

Institutional Investors Weigh In On Revolution Medicines

A number of institutional investors and hedge funds have recently modified their holdings of RVMD. Alphabet Inc. purchased a new position in Revolution Medicines during the 2nd quarter worth approximately $551,843,000. Assenagon Asset Management S.A. lifted its stake in Revolution Medicines by 987.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 2,181,185 shares of the company’s stock valued at $447,710,000 after acquiring an additional 1,980,699 shares during the period. Winslow Capital Management LLC acquired a new stake in Revolution Medicines during the 3rd quarter valued at approximately $260,191,000. Bank of America Corp DE purchased a new stake in shares of Revolution Medicines in the 2nd quarter valued at $184,267,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Revolution Medicines by 82.3% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 912,335 shares of the company’s stock valued at $170,862,000 after acquiring an additional 411,740 shares during the last quarter. Institutional investors and hedge funds own 94.34% of the company’s stock.

About Revolution Medicines

Revolution Medicines, Inc. is a biotechnology company focused on developing targeted therapies for patients with RAS-driven cancers. Founded in 2014 and headquartered in Redwood City, California, the company’s research centers on RAS proteins, which can contribute to the growth of many cancers. The company’s pipeline includes drug candidates designed to inhibit mutant RAS proteins, including daraxonrasib (RMC-6236), which targets multiple RAS variants, and candidates directed at specific KRAS mutations.